Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

The committee all agreed that tofersen presents a favorable risk-benefit profile in this particularly challenging patient population. 

FDA AdComm on Tofersen Supports NfL as Surrogate End Point of Clinical Benefit, But Is It Enough for Approval?

After results indicated significant slowing of ALS disease progression, Coya noted it plans to file an IND with the FDA in the second half of 2023 for a potential clinical study thereafter.

Treg Suppressing Agent COYA 302 Shows Slowing of ALS Disease Progression

If approved, ABBV-951 will become the first subcutaneous delivery of carbidopa/levodopa, often considered the standard of care for symptom management for patients with Parkinson disease.

FDA Issues Complete Response Letter for AbbVie’s 24-Hour Continuous Carbidopa/Levodopa Pump

The professor of neurology and pediatrics at University of Rochester Medical Center shared her thoughts on the 2023 MDA Clinical and Scientific Conference, and the progress made in the treatment of neuromuscular disorders. 

NeuroVoices: Emma Ciafaloni, MD, on Mounting Progress in the Neuromuscular Field, Duchenne Muscular Dystrophy

The neurologist and migraine expert from NYU Langone Health.

Videos

The neurologist and migraine expert from NYU Langone Health shared her reactions to the recently approved zavegepant nasal spray (Zavzpret; Pfizer) for the treatment of migraine. [WATCH TIME: 5 minutes]  

Newly Approved Migraine Nasal Spray Offers Alternative Treatment to Injections, Oral Medications: Shae Datta, MD

Slideshows

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

IJMSC Online First: March 2023

Director, Comprehensive Epilepsy Center, NYU Langone Health

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the importance of healthy eating habits and whether all individuals with epilepsy should consider dieting early in their life. [WATCH TIME: 4 minutes]

Importance of Establishing Healthy Eating Habits in Epilepsy: Orrin Devinsky, MD

The vascular neurologist at Cleveland Clinic provided an overview of a study that assessed the extent HbA1c impacts the relationship between mechanical thrombectomy and poor outcomes. [WATCH TIME: 3 minutes]

Effect of HbA1c Elevation, Glycemic Control Following Mechanical Thrombectomy: David Baker, DO

The headache migraine condition center is a resource for clinical news on the diagnosis, treatment, and management of headache migraine. |  NeurologyLive.


Headache Migraine | Clinical Neurology News & Insights | NeurologyLive

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

MDA 2023

NMOSD

Narcolepsy

Parkinson Disease

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1.125rem

Clinical

BIO-22-NRD0187 - /clinical/headache-migraine

 headache and migraine clinical focus page offers information, podcasts, videos, and news and interviews with physicians related to the care of patients with headache disorders such as chronic and episodic migraine, cluster headache, tension-type headache, and more. The page includes updates on the latest FDA actions, clinical guidelines, and study and clinical trial findings.

's featured content in the carousel below.

 to subscribe on your favorite streaming service.

 podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 67, "Mental Health and Advocacy in Pediatric Migraine," features an exclusive interview with Serena L. Orr, MD, MSc, pediatric neurologist, and headache specialist, University of Calgary, and Alberta Children's Hospital. She spoke about the recent work she's done looking into mental health conditions among pediatric patients with migraine, as well as how the field has progressed in managing the disease and advocating for these individuals.

. Check out new episodes every Tuesday and Thursday only on

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

FDA Advisory Committee Votes Down Pimavanserin's Efficacy in AD Psychosis Ahead of PDUFA

Parkinson Disease Symptom Data Tool StrivePD Receives FDA Clearance

AbbVie Submits Supplemental New Drug Application for Atogepant in Chronic Migraine

FDA Places Clinical Hold on Duchenne Muscular Dystrophy Drug SRP-5051 Amid Safety Concerns

FDA Pauses Tolebrutinib Trials in MS, Myasthenia Gravis Over Liver Injuries

Episode Breakdown

 podcast. Be sure to leave a rating and review for the show. Thanks for listening!

American Headache Society Annual Scientific Meeting

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Serena L. Orr, MD, MSc. [LISTEN TIME: 32 minutes]

Episode 67: Mental Health and Advocacy in Pediatric Migraine

Episode 63, "Moving Migraine Toward Personalized Care," features an exclusive interview with 

, director, MedStar Georgetown Headache Center, and associate professor of neurology, MedStar Georgetown University Hospital. She spoke about some recent data in headache medicine that has provided evidence of the in-clinic experience and how the migraine treatment landscape has shifted almost continuously in the past several years. As well, she touched on what challenges need to be addressed to achieve the goal of developing personalized treatment regimens for patients.

The stories highlighted in this episode's Neurology News Minute can be found here:

Axsome Issued CRL for AXS-07 in Acute Migraine Treatment

FDA Approves Ravulizumab for Adults With Generalized Myasthenia Gravis

FDA Permits Marketing for Plaque-Detecting Diagnostic Test for Alzheimer Disease

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jessica Ailani, MD. [LISTEN TIME: 35 minutes]

Episode 63: Moving Migraine Toward Personalized Care

Episode 61, "2022 AAN Annual Meeting Highlights," features interviews with a number of individuals who presented data and spoke at the American Academy of Neurology Annual Meeting, on topics ranging from COVID-19's clinical presentation, overall trends in the care of patients with multiple sclerosis, the potential of regenerative medicine in traumatic brain injury, the real-world and long-term use of new therapy for Lennox-Gastaut syndrome, the optimal timing for the newest therapy in neuromyelitis optica spectrum disorder, the Axon Registry and incorporating EHR information into its data collection, and the impact of the pandemic on clinician burnout and mental health. Those featured include Jennifer Frontera, MD; Stephen Krieger, MD; Peter McAllister, MD; Kelly Knupp, MD, MSCS; Bruce Cree, MD, PhD, MAS; Shrujal Baxi, MD, MPH; and Indu Subramanian, MD.

Note: As part of AAN policy for the Annual Meeting, all individuals were asked to remain masked throughout the week, so there may be some moments of muffled noises as participants adjust or shift their masks.

Click here for more coverage of AAN 2022.

American Academy of Neurology Annual Meeting

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Jennifer Frontera, MD; Stephen Krieger, MD; Peter McAllister, MD; Kelly Knupp, MD, MSCS; Bruce Cree, MD, PhD, MAS; Shrujal Baxi, MD, MPH; and Indu Subramanian, MD. [LISTEN TIME: 32 minutes]

Episode 61: 2022 AAN Annual Meeting Highlights

 podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

Episode 55, "Treating Headache in the Emergency Department," features an exclusive interview with Anne-Maree Kelly, MD, MClinEd, FACEM, senior emergency physician, Western Health; director, Joseph Epstein Centre for Emergency Medicine Research; professorial fellow, the University of Melbourne; and adjunct professor, Australian Centre for Health Law Research, Queensland University of Technology. She shared her clinical experience treating patients with headache and migraine in the emergency department (ED), offering insight into the factors that influence patient outcomes and the vital need for consensus international guidelines for ED migraine care.

5-SENSE Score Validated for Seizure-Onset Zone Identification, May Improve Patient Eligibility for Epilepsy Surgery

FDA Approves Daridorexant for Insomnia Treatment

CMS Releases Proposed Decision for Aducanumab Coverage in Alzheimer Disease

REFERENCES
Kelly AM, Kuan WS, Chu KH, et al. Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)–a multinational observational study. 

. 2021;61(10):1539-1552. doi:10.1111/head.14230

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Anne-Maree Kelly, MD, MClinEd, FACEM. [LISTEN TIME: 23 minutes]

Episode 55: Treating Headache in the Emergency Department

Episode 54, "The Shortage of Neurologists," features an exclusive interview with Jennifer Majersik, MD, MS, chief, division of vascular neurology, and professor of neurology, University of Utah, who along with 9 other colleagues, authored a report from the American Academy of Neurology (AAN) 2019 Transforming Leaders Program on the ongoing shortage of physicians in neurology. She offered her perspective on the challenge and how it can be addressed from an individual and institutional level.

REFERENCES
Majersik JJ, Ahmed A, Chen IA, et al. A shortage of neurologists – we must act now: A report from the AAN 2019 transforming leaders program. 

. Published online April 30, 2021. doi:10.1212/WNL.0000000000012111

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Majersik, MD, MS.

Episode 54: The Shortage of Neurologists

The Mind Moments™ podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

Episode 52, "Treating Pediatric Migraine," features an exclusive interview with Christina Szperka, MD, MSCE, assistant professor of neurology, and director, Pediatric Headache Program, Children's Hospital of Pennsylvania. She offered up her thoughts on the current state of clinical care and awareness of pediatric migraine and shared her insight into the changes the landscape of treatment has undergone.

AAN Issues Statement on Ethical Considerations for Aducanumab Use in Alzheimer Disease

Enrollment Complete for Phase 2 Study of ATH-1017 in Moderate Alzheimer

FDA Accepts sNDA, Grants Priority Review to Fenfluramine for Lennox-Gastaut Syndrome

 to subscribe to the Mind Moments™ podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Szperka, MD, MSCE.

Episode 52: Treating Pediatric Migraine

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 46, "Tackling Barriers to Migraine Care," features an exclusive interview with Deena Kuruvilla, MD, director, Westport Headache Institute, who spoke to the current state of affairs in the clinical care of migraine. She also shared her insight into the issues that specialists need to overcome, such as access to therapy, the real-world use of novel treatments for headache disorders, and the advances that are currently in the research and development stage.

The stories feature in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

FDA Approves Vivistim VNS System for Ischemic Stroke Motor Deficits

FDA Approves Brivaracetam for Partial-Onset Seizures in Pediatric Epilepsy

 to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Deena Kuruvilla, MD.

Episode 46: Tackling Barriers to Migraine Care

Episode 36, "Zavegepant and the Gepant Class for Migraine Care," features interviews with Elyse Stock, MD, chief medical officer, Biohaven Pharmaceuticals, and Thomas Shiovitz, MD, director of California Neuroscience Research, to discuss the recently initiated phase 2/3 clinical trial of zavegepant, an oral CGRP-targeting agent for the prevention of migraine developed by Biohaven. The duo discusses how the investigational treatment fits into the gepant class and the impact that the gepants have had on migraine care overall.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Elyse Stock, MD, and Thomas Shiovitz, MD.

Episode 36: Zavegepant and the Gepant Class for Migraine Care

Episode 35, "Highlights From the AAN Annual Meeting," features interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD. Each of them discussed data that they respectively presented at the American Academy of Neurology Annual Meeting. These presentations included novel tools for tracking cognitive decline, analyses of subpopulations of patients with migraine treated with new medicines, the disparities faced by women and Black individuals going through stroke rehabilitation, and more.

REFERENCES
1. Nahas S, Ning X, Cohen JM, Barash S, Campos VR, Silberstein SD. Efficacy of fremanezumab in patients with moderate and higher frequency episodic migraine. Presented at 2021 American Academy of Neurology Annual Meeting. Abstract P10.046
2. Nahas S, Jurgens TP, Kessler Y, et al. Cardiovascular safety of fremanezumab in patients with migraine and cardiovascular medical history or risk factors: A pooled analysis of phase 3 studies. Presented at 2021 American Academy of Neurology Annual Meeting. Abstract P10.034
3. Cree B, Bennett J, Weinshenker B, et al. Long-term efficacy outcomes with inebilizumab treatment in NMOSD: the N-MOmentum trial. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.076
4. Cree B, Bennett J, Weinshenker B, et al. Long-term safety outcomes with inebilizumab treatment in NMOSD: the N-MOmentum trial. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.100
5. Somani S, Nanavati H, Xiaohua Z, Lin C. African American women have lower functional performance during acute inpatient rehabilitation after intracerebral hemorrhagic strokes. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P5 073
6. Fernandez H, Odin P, Standaert D, et al. Identifying gaps in Parkinson disease patients eligible for device-aided therapies: results from using the MANAGE-PD tool in patients from G7 countries. Abstract P14.117
7. Ontaneda D, Qu J, McGinley M, et al. A Data Driven Approach to Define Disease Course Categories in MS. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.244
8. Pila S, Novak M, Weintraub S, et al. The Mobile Toolbox (MBT): A Completely Remote Platform for Cognitive Research. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P7.086

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD.

Episode 35: Highlights From the AAN Annual Meeting

Episode 32, "The Gaps in Migraine Care for Women," features an interview with Brian Grosberg, MD, director, Hartford Headache Center, and professor of neurology, University of Connecticut School of Medicine, about the results of a recently published study he and colleagues conducted that assessed the knowledge of women’s healthcare providers such as OB/GYNs in the management of migraine in their patients—a patient population that is mostly women.

REFERENCE
Verhaak AMS, Williamson A, Johnson A, et al. Migraine diagnosis and treatment: A knowledge and needs assessment of women’s healthcare providers. 

. 2021;61(1):69-79. doi: 10.1111/head.14027.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Brian Grosberg, MD.

Episode 32: The Gaps in Migraine Care for Women

Here's some of what is coming soon to NeurologyLive® this week.

This Week on NeurologyLive® — March 20, 2023

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 17, 2023.

NeurologyLive® Friday 5 — March 17, 2023

In honor of Brain Awareness Week, a group of experts in the care of patients with neurological conditions—Ronald C. Petersen, MD, PhD; Brian Grosberg, MD, FAHS; James Beck, PhD; Michael Levy, MD, PhD; Stanley H. Appel, MD —shared their perspectives on hot topics of treatment and management in neurology.


NeurologyLive® Top Expert Interviews: Brain Awareness Week

This Week on NeurologyLive® — March 13, 2023

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 10, 2023.

NeurologyLive® Friday 5 — March 10, 2023

"Our theory of change, at its core, is about the power of storytelling and putting a face, a name, and a compelling story of real life people and how they relate to our asks. That’s how we can motivate our legislators to care about these issues."

Over the years, there has been significant progress made in the treatment of migraine, an illness that affects nearly 40 million people in the US. Monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway, a protein linked to migraine symptoms, have continued to revolutionize the field as well. While the treatment toolbox available to clinicians has expanded, there still remains policy issues with regard to access and coverage of certain therapeutics and specific age groups, such as young children.

Headache on the Hill, a 1-day event held annually by the Alliance for Headache Advocacy, is considered the most influential day of the year in headache advocacy. Here, volunteer advocates come together to personally present Congress with requests or “asks” that aim to change legislation affecting the headache community. This year’s event, held February 14th, included nearly 300 advocates with connections to 49 states.

To learn about the preparation for the event, along with the decision process that goes into these asks, 

, executive director of the Alliance for Headache Disorders Advocacy. Verdi spoke on several points, noting that these changes do not occur unless members of Congress, and the country as a whole, takes migraine more seriously. She discussed which community members the organization reaches out to, and why personalizing the experiences of those with migraine can ultimately lead to better long-term solutions.

The executive director of the Alliance for Headache Disorders Advocacy provided perspective on the preparation that goes into Headache on the Hill, and the parties involved in this process. [WATCH TIME: 5 minutes]

SAP Partners

Planning for Headache on the Hill Through Community Outreach, Research: Julienne Verdi

"There’s a lot of work to be done. Where do these problems arise? I’d say from a lack of appreciation for the seriousness of headache disorder. So often these conditions are just dismissed as just a headache, and we know there’s much more than that."

Migraine remains one of the world’s most common health conditions and its most common neurological disease. Roughly 40 million people in the US and 1 billion people worldwide have migraine, making it the third most common illness in the world. Women face a much higher risk of experiencing migraines than men; although, the reasons for this are not fully understood.

Headache on the Hill is an annual event in Washington, D.C., put on by the Alliance for Headache Disorders Advocacy (AHDA) that offers volunteer advocates to bring forth major topics of concern in the headache community. It remains the only annual advocacy day exclusively dedicated for advocating for equitable federal policies for those with headache disorders. This year’s meeting, which was held on February 14, was the largest and most diverse cohort of advocates to date, with nearly 300 advocates from 49 states attending.

To learn more about the legislative requests brought up this year’s Headache on the Hill, 

 sat down with Julienne Verdi, executive director of AHDA. Verdi, a lawyer, highlighted the 3 main asks the organization presented, the first of which dealt with establishing a Congressional Caucus for Headache Disorders. Additionally, she provided perspective on the need to expand services for children with migraine and other severe headache disorders, as well as the reasons for the reintroduction of the Care for Long COVID ACT.

The executive director of the Alliance for Headache Disorders Advocacy delved into the critical access and policy issues expressed at the 2023 Headache on the Hill. [WATCH TIME: 7 minutes]

Policy Changes Needed to Improve Migraine Care and Access to Treatments: Julienne Verdi

“This study highlights the need to continue to talk about [migraine management during pregnancy] and continue to provide education that's readily available to people. Just keep talking about it and hopefully we can improve the care for patients get in regard to their migraines during pregnancy.”

Headache specialists and women’s healthcare providers have differing opinions and experience with patients who have migraines during pregnancy. Therefore, they might have contrasting recommendations for pregnant patients seeking out treatment for their migraines. Having more awareness on different types of migraine management available to pregnant patients may direct clinicians to recommend the most effective treatment to their patients.

 recently published findings on a survey of 92 women's healthcare providers that showed different levels of comfort for prescribing treatment for migraines during pregnancy.

 From the total respondents, 26% of providers counseled women on migraine treatment during pregnancy before pregnancy contemplation, and over 35% counseled for migraine treatment at pregnancy conception.

Women’s healthcare providers felt somewhat or very comfortable to recommend (63%) or continue (64%) acute treatments for pregnant patients with migraine. The highest levels of comfort for providers reported recommending or prescribing acetaminophen (100%) and prescribing (94% [85 of 90]) or continuing caffeine (91% [82 of 90]). Higher levels of discomfort were reported in 88% (n = 80) out of 91 providers with recommending or prescribing triptans during pregnancy for migraine. Forty percent of respondents felt less comfortable with recommending preventive migraine care to patients, compared with 63% who were somewhat or very comfortable with patients continuing preventive medications.

Stephanie Bakaysa, MD, maternal fetal medicine specialist at Hartford HealthCare Medical Group, sat down with 

® in a recent interview to discuss the findings from the study. She spoke the surprising results and also some of the common themes observed in her clinical practice. In addition, Bakaysa mentioned the current challenges with recommending treatments for migraine during pregnancy between headache specialists and women healthcare providers.

REFERENCES
1. Verhaak A, Bakaysa S, Johnson A, Veronesi M, Williamson A, Grosberg B. Migraine treatment in pregnancy: A survey of comfort and treatment practices of women's healthcare providers. 

. 2023;10.1111/head.14436. doi:10.1111/head.14436

The maternal fetal medicine specialist at Hartford HealthCare Medical Group talked about the challenges of prescribing migraine treatment during pregnancy. [WATCH TIME: 4 minutes]  

Migraine Management During Pregnancy, Women’s Healthcare Providers vs. Headache Specialists: Stephanie Bakaysa, MD

“This really emphasizes the need for the development and implementation of interdisciplinary guidelines both between headache specialists and women's healthcare specialists for optimally treating migraine during pregnancy.”

Research shows that there is an association between migraine and both maternal and fetal complications. Hence, understanding the awareness and levels of comfort for treatment with women’s healthcare providers is essential in research. Additionally, the knowledge of women of certain medications prior to conceiving is important to comprehend as they might benefit more from information related to nonpharmacological treatments that focus on lifestyle changes. 

According to a recent survey of 92 women's healthcare providers conducted by the 

, findings demonstrated a variety of levels of comfort for migraine treatment during pregnancy.

Notably, 26% of respondents reported they counseled women on migraine treatment during pregnancy before pregnancy contemplation, whereas over 35% counseled for migraine treatment once the patient became pregnant.

The medical director of the Hartford healthcare Headache Center in Connecticut discussed the significance of findings from a study assessing migraine during pregnancy. [WATCH TIME: 4 minutes]  